No more RCT's? Validity of research

Rob de Bie Professor of Physiotherapy Research Director of education Faculty of Health Caphri research School Department of Epidemiology Maastricht University



Contents

- Gold standard of research
- Why (bother with) validity?
- We think we measure study quality
- Examples of non-evidence
- A possible solution



Gold standard?

- Experiment
- Cohort study
- Patient-control study
- Patient series
- Case study



Amount of improvement



Consequences of effect studies

- more negative studies > loss of faith
- loss of faith > loss of competence
- loss of competence > decreased performance
- decreased performance > ineffective treatments
- ineffective treatments > negative studies

What is validity?

- Cook and Campbell (1979) define it as the "best available approximation to the truth or falsity of a given inference, proposition or conclusion".
- Measuring what you want to measure

Why validity?

- Credibility of research and research findings at large
- Has been done what I read?
- Quality of research relevant for:
 - Primary trials
 - Reviews
 - Guidelines

When research credibility is compromised.....



SEOUL, South Korea - South Korean researcher Hwang Woo-suk resigned from his university after the school said he fabricated stem-cell research that had raised hopes of new cures for hardto-treat diseases. *Dec 2005*

Internal/external validity

- Internal validity research conclusions are valid for the studied population
- External validity –research conclusions are also valid for other populations (not from the current research sample) - generalisability

Previous experiences with talks about research methodology....



Definition of guidelines

Systematically developed statements which assists clinicians and patients in making decisions about appropriate treatment for specific conditions (Mann, 1996)

History (in reality)

- Formalized statement of daily practice
- Organizational basis
- Describes rather the context than the intervention





Ambroise Paré: treatment on the battlefield



More recently, (clinical) guidelines have emerged

- Consensus based
- Expert based
- Evidence based



Consensus based

- Consensus may be largely influenced by group dynamics
- Delphi method does not entirely solve this problem

Consensus = non-sensus Consensus guidelines are guidelies

Expert based

- Might be even worse than consensus
- Expert bias
- Centripetal bias
- Opinion bias
- Prejudice
- External financing

Evidence based

- Guideline recommendations are based on best available evidence
- Deals with specific interventions for specific populations
- Are based on a systematic approach

EBP is the VOODOO of the 3rd millennium



Is the evidence ...

- Good enough
- Transparent
- Credible
- Available
- Applied
- Not 'muddled' by health care insurers





Some trials are never done!



Risks of downhill skiing studied in animal research



Risks of not wearing a parachute when jumping from an aeroplane

Informativeness:

what you read is not what has been done



Quality of a trial versus publication year



Systematic reviews: quality and estimate of efficacy



Jadad & McQuay J Clin Epidemiol 1996

Effect shrinkage (Suttorp et al, 2006)

Quality items	ES ratio	95% CI
Sum score > 5	0.62	0.37 – 0.96
Sum score > 4	0.61	0.42 - 1.06

Methodological quality items are associated with bias and a sum score threshold of higher than five is significantly associated with bias.

The better the trial...

- The less likely there will be a result
- selection bias?
- exclusion of co-morbidity?
- ceiling and floor effects?





Methodological approach

Nested trial cohort studies



Example: intermittent claudication

- There are EB guidelines available
- There is already sufficient evidence
- There is a network of trained health care providers
- There is an integrated ICT environment ready for research

Intermittent Claudication or Peripheral Arterial Disease (PAD)

- Walking-induced pain in one / both legs
- Complaints disappear after rest
- Decreased ability to perform activities
- Rest or nocturnal pain
- Small wounds
- Calcification of nails
- Loss of hair
- Tissue loss



Epidemiological Data:

Prevalence:

1.6 % (Rutgers, 1998) 2.0 % (Kaiser, 1999)

Incidence:

2.8 per 1000 patients / yr 0.4‰ 25-44 year 10.6 ‰ > 75 year (Lamberts 1994, Kaiser, 1999)



Natural Course

- 75%: stable or minor improvement of symptoms
- 25%: serious complaints in < 5 yr
- 2-5%: amputation
- Within 10 years: 21%: stroke 43%: Coronary Heart diseases
- Life expectancy < 10 yr



Peripheral Arterial Disease (PAD) and All-Cause Mortality*1



*Kaplan-Meier survival curves based on mortality from all-causes *Large-vessel PAD

1. Criqui MH. Vasc Med 2001; 6(suppl 1): 3-7.



Riskfactors

Genetic Infection? Gender Age

.....

Smoking Diet Physical inactivity Obesity

Diabetes type-2 Hypertriglyceridemia Hypertension Metabolic syndrome

Interventions for PAD

- Riskfactor management
- Medication
- Behavioral life style changes

Stop smoking (no. 1 target)

- Exercise training / increase walking ability
- Co-morbidity need targeted interventions (e.g. COPD, diabetes, heart diseases)
- Vascular surgery



Etalagebenen







Inbox - Mic...

<

Done

🛃 start



🔂 Microsoft A...

Home Patiënten Professionals Netwerken Richtlijn Links Contact

WELKOM OP DE SITE

Deze interactieve claudicatio intermittens website is bedoeld voor fysiotherapeuten, artsen, nurse practitioners en patiënten. Professionals kunnen via deze website het elektronische dossier van hun patiënten invullen en bijhouden. Het Elektronische Patiënten Dossier (EPD) vervangt het papieren dossier en bevordert de onderlinge communicatie. De patiënt kan het eigen dossier inzien en onderdelen zoals bijvoorbeeld vragenlijsten zelf invullen.

Wat zijn etalagebenen precies?

Claudicatio Intermittens (CI) wordt in de volksmond ook wel etalagebenen genoemd en wordt in meer dan 90% van de gevallen veroorzaakt door slagaderverkalking (atherosclerose). CI is een uiting van perifeer arterieel vaatlijden (PAV), waarbij sprake is van atherosclerose van of naar de slagaders van de benen. Van PAV hoeft een patiënt geen klachten te ervaren. Wanneer de patiënt met PAV klachten ervaart van pijn in één of beide benen tijdens inspanning die vervolgens verdwijntna het nemen van enige minuten rust spreken we van claudicatio intermittens (CI).

Wat kunt u zelf doen?

De klachten zijn vervelend, maar hoeven geen ernstige gevolgen te hebben. Het is vooral belangrijk om tijdig actie te ondernemen. Een belangrijk deel van de behandeling heeft u in eigen hand. Stoppen met roken, de juiste hoeveelheid beweging en eventueel afvallen zijn de belangrijkste aandachtspunten. Verder is een goede voetverzorging belangrijk om te voorkomen dat de

🗀 2 Window... 👻 🛛 2 Microso... 🔹 🌈 ETALAGEBE...





🎯 🌈 🧿 🦉 😼 📴 🛛 🖉 🧶 🕲 🖉 🔼 N 09:33

\Theta Internet

100%

🖉 Rob de Bie En	kelletsel CEBP - Windo	ws Internet Explorer					
🚱 🕤 👻 http://www.enkelletsel.nl/portal/?FFID=6900							
File Edit View	v Favorites Tools Help	o 🕴 Links 🙋 Customize L	inks 🧧 Free Hotmail 🛛 🔀 Goo	gle 🛛 🔊 Windows 🛛 🕸 Windows Marketplace	🤕 Windows Me	edia	
😭 🏟 🍘 Rob	de Bie Enkelletsel CEBP			🙆 • 📾 • 🖶	• 🔂 Page • (🗿 Tools 🔻 🔞 🕈 🔯	3
Basis Tools	CRM Sitemanager	Webmed				A 3	
(n. i.	Ϋ́́						T.
Patienten	Groepen	n an Artan an Artan					-
	zoek A B C	DEFGHIJ	KLMNOPQRS	TUVWXYZ*			-
Voornaam	Tussenvoegsel	Achternaam	Telefoonnummer	E-mail	Edit	E-mail pt Brief pt	-
🖽 Daan	van der	Aa		daanisweg@hotmail.com	3	0	
🗄 Ben C.M.		Agterberg	0478-583643	m.agterberg@home.nl	3	0	
🖽 Richard		Andersen	06-42578274	geen email	3	0	
🖽 Miriam	van	Beem	0487-518453		3	0	
🗄 Sandra		Beenkens		sandrabeenkens@home.nl	3	0	
🖽 Hans	van	Beers	06-46042628	Geen patient!	3	O	
🗄 Wendy		Blijleven	06-28245613	wblijleven@quicknet.nl	3	0	
🗄 Peter		Bluemink		www	3	0	
🗄 Mark w.	Van den	Boogaard	015-3107734	mark_song113@hotmail.com	3	0	
🗄 Frank	van de	Boomen	040-2547270	f_vd_boomen@hotmail.com	3	0	
1 2 3 4 5	6 • ••						
							~
http://www.enkelletse	el.nl/portal/?FFID=6905&PAT	TENT=169			🕑 Internet	a 100%	•
🐮 start 🔰	🔟 Inbox - Mi 😣) Microsoft 🏻 🛅 2. Win	do 👻 💯 2 Micros 👻	🜈 Rob de Bie 🤰 🥵 🌈 🧿 🤭	S 0 V :		19:42





۰ 🕤	🦲 https:/	//claudica	atio.cebp.nl/portal	/?FFID=6701&GRAF=6			✓ 월 49 ×	Google		P
ogle G-		~	Uitvoeren 🚸 🧭	😂 🖂 💍 🕇 😭 ві	adwijzers 🗸 😽 Spel	ling controleren 👻 🔒 V	/erzenden naar 👻 💋		() Instellinge
* 88	▼ 🏉 Ro	b de Bie	CEBP	CRob de Bie Claudica	tio Int ×		6	• 🔊 - 🖶	🔹 📝 Pagina 👻	💮 Extra 🗸
sis Too	ls CR	M S	itemanager	Webmed					🏫 🛞	
ijst queries	s	Qu	ery wizzard]						
raaitabel		Opn	nerkingen	Loopafstanden 1	Loopafstanden 2	Loopafstanden	3 Statistieken			
2										
o Onderst	aande g	jegeve	ens zijn gebas	eerd op alle patiente	en die een loopaf	stand hebben afge	legd ongeacht de me	etingsoort		
Pat	tient Sta	tistie	ken .	Max DV		— Gemiddelde Max	alle patienten — Standaa	ddeviatie (Max)		
Туре		lantal	Percentage	🗹 Man 📃 Vrou	w	- Max afstanden Pa	atient	ado Hallo (Hax)		
nnen		107	100	Diabetici						
ouwen		0	0	COPD						
abetici		25	23.4	O Huidia Roker	18	³⁰⁰ Г				
		28	26.2			-				
aft Careals		107	100	Heeft Gerookt	16	600 -				
eit Gerook		107	100	Nooit Gerookt		-				
off Gerook	L He	70,90	U	Niet Filteren	14	100 -				
entija berei middalda l	K.	70-60		Leeftijd	ŝ			\sim		
iniddeide i	eertiju	/4./		Van 70 Tot 80	j 12	200				
	patiente	11: 107			(We					
Gra	afiek Sta	atistie	ken .	Filter	210					
Meting	Aanta	ГР	ercentage		sta	200 [/				
seline	107		100		, paí					
laand	54		50.5		8	200				
laand	52		48.6		_ (
laand	39		36.4		,					
Maand	9		8.4		-					
Maand	21		19.6			000				
taal aantal	patiente	n: 107			-					
						0 5 10 15	20 25 30 35	40 45 5	0 55	

Average maximal walking distance (+ 95% CI) men (n=698)

Average maximal walking distance (+ 95% CI) women (n=408)



no co-morbidity

1

Average maximal walking distance (+ 95% CI) smoking men

Average maximal walking distance (+ 95% CI) smoking women



Average maximal walking distance (+ 95% CI) men with COPD

Average maximal walking distance (+ 95% CI) women with COPD



no co-morbidity

whole conort





Average maximal walking distance (+ 95% CI) women with diabetes



no co-morbidity

whole cohort

Shift in prognostic factors











Thank you!

Further info: www.cebp.nl

Maastricht University